May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
THE INTERNATIONAL COLLABORATIVE EXFOLIATION SYNDROME (XFS) TREATMENT STUDY (ICEST): study design, methods, and baseline data of enrolled patients.
Author Affiliations & Notes
  • R. Ritch
    The New York Eye and Ear Infirmary, New York, NY
  • V. Hugo
    The New York Eye and Ear Infirmary, New York, NY
  • T. Krupin
    University Eye Specialists, Chicago, IL
  • A. Konstas
    AHEPA Hospital, Thessaloniki, Greece
  • J. Liebmann
    The New York Eye and Ear Infirmary, New York, NY
  • E. Ilitchev
    The New York Eye and Ear Infirmary, New York, NY
  • M. Marmor
    New York University School of Medicine, New York, NY
  • ICEST Study Group
    The New York Eye and Ear Infirmary, New York, NY
  • Footnotes
    Commercial Relationships  R. Ritch, None; V. Hugo, None; T. Krupin, None; A. Konstas, None; J. Liebmann, None; E. Ilitchev, None; M. Marmor, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2108. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Ritch, V. Hugo, T. Krupin, A. Konstas, J. Liebmann, E. Ilitchev, M. Marmor, ICEST Study Group; THE INTERNATIONAL COLLABORATIVE EXFOLIATION SYNDROME (XFS) TREATMENT STUDY (ICEST): study design, methods, and baseline data of enrolled patients. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2108.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the efficacy of treatment with latanoprost in combination with pilocarpine versus timolol or timolol/dorzolamide fixed combination (Timoptic or Cosopt) in eyes with XFS and elevated intraocular pressure (IOP). Methods: This is a randomized, open–label study to test the hypothesis that improving both pressure–dependent and pressure–independent aqueous outflow and minimizing iridolenticular friction will interfere with the progression of XFS, allow improvement in trabecular function, and be more effective over time than simply reducing aqueous formation. Randomization was performed across the centers, per patient rather than per eye to avoid any crossover effect caused by aqueous suppressants. Group I was treated with latanoprost and pilocarpine, both in the evening, and Group II with Timolol or Cosopt b.i.d. Only one eye per patient was randomized. Patients were followed for 2 years with assessment of IOP, visual field progression, tonographic outflow coefficient and trabecular pigmentation at the 6:00 and 12:00 position. Results:A total of 277 patients with XFS and elevated IOP with and without glaucoma were enrolled at 12 centers in 7 countries between October 3, 2000 and July 4, 2003. The mean age was 69 years; 146 (52.7%) of the subjects were men and 131 (47.3%) were women. Clinically unilateral XFS was present in 118 (42.6%) patients and bilateral XFS was present in 159 (57.4%). Trabecular meshwork pigmentation at the 6:00 angle in the treated eye, graded on a scale from 1 to 5, was significantly associated with IOP (p=0.01), but not with the outflow coefficient, sex, or age. Among the 277 patients, 150 (54.2%) were treated in the right eye and 127 (45.8%) in the left. Latanoprost and pilocarpine were assigned to 145 (52.3%) and Timolol or Cosopt to 132 (47.7%). Conclusion: The ICEST study should provide us with guidance on the best initial treatment for patients with XFS and elevated IOP.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • clinical research methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×